Leadership & Pay ·
Relmada Therapeutics, Inc. announced the appointment of Bipin Dalmia, PhD, MBA, as its new Chief Business Officer on…
RLMDRelmada Therapeutics, Inc.
Relmada Therapeutics, Inc. announced the appointment of Bipin Dalmia, PhD, MBA, as its new Chief Business Officer on July 28, 2026. Dalmia brings nearly three decades of biopharmaceutical leadership experience, including roles at Ferring Pharmaceuticals, Biolex Therapeutics, Syngenta, and Novartis, with specific expertise in corporate strategy, business development, and non-muscle invasive bladder cancer (NMIBC). He will report directly to CEO Sergio Traversa and lead the company's commercial planning and strategic initiatives as it advances its lead candidate, NDV-01, toward late-stage development. Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders.